Why Great Life Sciences Products Fail: The Science of Market Adoption with Holley Miller

Why Great Life Sciences Products Fail: The Science of Market Adoption with Holley Miller

Why do nearly two-thirds of healthcare and life sciences product launches fail, even when the technology is groundbreaking? In this episode of the Life Sciences Sales Lab, host Shannon J. Gregg sits down with Holley Miller, founder and president of Gray Matter, to explore the critical gap between innovation and adoption. Drawing from more than 20 years of experience in life sciences marketing and commercialization, Holley explains why "if you build it, they will come" is one of the most expensive assumptions companies make. She shares practical insights on how organizations can engineer market belief, create demand before launch, and position their innovations as must-have solutions rather than nice-to-have products. Key topics include: * Why healthcare product launches fail * The psychology behind market adoption * Creating belief before commercialization * Aligning sales, marketing, and medical education teams * Lessons from the early days of surgical robotics * Building sustainable growth trajectories for life sciences companies If you're involved in medical devices, biotech, pharmaceuticals, healthcare innovation, or life sciences sales and marketing, this conversation delivers actionable strategies to help your next launch succeed.

The Compliance Edge: How Life Sciences Sales & Marketing Are Evolving with Darshan Kulkarni

In this episode of the Life Sciences Sales Lab, Dr. Shannon Gregg sits down with Darshan Kulkarni — attorney, pharmacist, educator, and one of the most fascinating minds in the life sciences industry. From being a 6th-generation pharmacist to building expertise across law, compliance, business, and healthcare, Darshan shares his unique journey and deep insights into the evolving world of pharmaceutical sales and marketing. The conversation dives into the intersection of innovation, regulation, compliance, and commercialization in life sciences. They explore how modern sales and marketing teams can thrive in highly regulated industries, why intellectual curiosity matters more than ever, and how compliance can actually become a competitive advantage instead of a limitation. If you're in pharma, biotech, healthcare marketing, medical affairs, or life sciences sales — this episode is packed with insights you won’t want to miss.

From One User Group to a Global Movement with Eric Dreshfield

What happens when you can’t attend the conference you’ve been dreaming about? For Eric Dreshfield, the answer was simple: create his own. In this inspiring episode of the Life Sciences Sales Lab, host Shannon J. Gregg sits down with Salesforce legend Eric Dreshfield to explore how authentic relationships, curiosity, and community-building transformed his career. Eric shares his remarkable journey from attending local Salesforce user groups to founding Midwest Dreamin'—a grassroots conference that sparked a worldwide movement of Dreamin’ events. Along the way, he reveals how networking led directly to career opportunities in life sciences and why helping others has become the cornerstone of his personal brand. This episode is packed with practical insights for anyone looking to grow their career, expand their network, and turn one idea into a lasting impact.

The $16 Billion Post-Mortem: Why Enterprise Deals Fail at the Finish Line with Natalie Bulger

In this episode of Life Sciences Sales Lab, Dr. Shannon Gregg is joined by Natalie Bulger to perform a forensic analysis of the VA’s $16 billion EHR transformation. For a sales executive, a signed contract is only the beginning; the real battle is surviving the "Last Mile" of implementation where fragmented leadership and "shadow workflows" can derail even the most strategic enterprise win. Natalie shares "war stories" from the front lines of the VA rollout, offering a masterclass in identifying the hidden organizational landmines that turn a flagship deal into a "Hamster Wheel" of endless technical debt. If you are selling eClinical or healthcare technology to complex, multi-layered organizations, this conversation is your blueprint for protecting your footprint and ensuring long-term account viability. Key Takeaways for Sales Leaders: The "Shadow" Org Chart: Why selling to the C-suite isn't enough if you haven't mapped the disconnected IT silos that actually control the "Go-Live". M&A and Leadership Volatility: How to "insulate" your deal against the leadership turnover that frequently follows a major acquisition or contract award. The "Anti-Agile" Reality: Why rushing a Minimum Viable Product (MVP) into a clinical setting is a recipe for "Defiant Adoption" and lost renewals. Closing the Value Gap: Moving the conversation from "Software Features" to "Risk Mitigation" to ensure your tool remains a "must-survive" asset during budget cuts.

AI in Life Sciences Sales: What’s Real vs What’s Hype in 2026 with Dr. Shannon J. Gregg, PhD

In this episode of the Life Sciences Sales Lab podcast, Shannon explores one of the biggest conversations shaping commercial organizations today: AI in life sciences sales. With constant pressure to move faster, improve execution, and stay competitive, artificial intelligence is becoming impossible to ignore. But amid all the excitement, what’s actually delivering value—and what’s simply industry hype? This episode breaks down: • Where AI is genuinely improving commercial performance • Why productivity and prioritization matter more than flashy tools • The biggest misconceptions leaders should avoid • How adoption, trust, and execution still determine success • Why human relationships remain the foundation of life sciences sales If you're a commercial leader trying to separate meaningful innovation from noise, this conversation offers a practical perspective on how organizations can use AI thoughtfully in 2026 and beyond.